it is now being increasingly proffered for purposes of drug screening and development (Wesnes et ai., 1991; Christensen et ai., 1992; Sahakian et ai., 1993) .
We previously reported a problem in this modei. AD is characterized by a typical parietotemporal deficit in cortical metabolism and blood flow (Friedland et ai., 1983; Jagust et ai., 1987; Prohovnik et ai., 1988) .
In contrast, we (Honer et ai., 1988) have shown that scopolamine causes a frontal, rather than a pari etotemporal, cortical perfusion deficit. Therefore, scopolamine-induced amnesia appears to depend on cerebral networks different from those affected by AD. This suggestion is consistent with reported dis crepancies between the neuropsychological profile of AD and that of scopolamine-induced deficits in normals (Lines et ai., 1991) and differences between scopolamine effects on visual evoked responses and the effects of AD (Ray et ai., 1991) .
We previously replicated the hypofrontal scopol amine effect on cerebral perfusion in a pharmacologi cally complex situation, following nicotinic blockade (Gitelman and Prohovnik, 1992) . The current experi ment was undertaken to directly replicate the scopol amine effect and verify its central cholinergic mecha nisms. Specifically, we tested whether the amnesic and regional cerebral blood flow (rCBF) effects of scopolamine could be attributed to nonspecific side effects or systemic factors, rather than a specific CNS anticholinergic effect. The current design replicates our previous experiments but uses physostigmine (a centrally active cholinesterase inhibitor) and neostig mine (a peripheral cholinesterase inhibitor) for rever sal following scopolamine injections. Since physostig mine has demonstrated efficacy in the treatment of AD and has been claimed to reverse the AD-like cognitive deficits induced by scopolamine (Wesnes et ai., 1991) , we tested whether such a reversal would occur in our model and whether it would be accompa nied by reversal of the rCBF abnormality. The neo stigmine condition provided a control for the periph eral cholinergic agonism of physostigmine.
METHODS
Other than changes related to the pharmacological rever sals, all procedures were identical to those employed by Honer et al. (1988) . All time points are denoted in relation to scopolamine injection, unless otherwise noted.
Subjects
Ten healthy young subjects were recruited. One was dropped owing to marked hypotensive bradycardia in re sponse to neostigmine, yielding a final sample size of nine. All were male, with a mean age of 25 ± 5 years (range 19-35 years).
Design
All subjects visited the laboratory for initial screening and then twice for the experimental procedures. The proce- o  20  40  60  80  100   Time [min] FIG. 1. Buschke Selective Reminding scores (total recall, mean ::+: SD) by time (minutes relative to scopolamine injection) and AChE inhibitor (physostigmine versus neostigmine). The striped rectangle indicates the time of AChE inhibitor infusion. Scopol amine impairs recall, but the impairment is briefly ameliorated by physostigmine infusion. dures were identical on both days and were performed at the same time of day, except for the randomized order of either physostigmine or neostigmine. Baseline procedures included the Buschke Selective Reminding Test (BSRT; Buschke, 1973) and rCBF measurement by the Xenon 133 inhalation technique. Scopolamine (7.2 JLg/kg i.v.) was then administered, and a second rCBF (run 2) was begun 5 min after the injection. Two minutes before the end of this procedure, a slow infusion of either physostigmine (22 JLg/ kg) or neostigmine was started, which lasted 10 min. The first five subjects received a neostigmine dose of 11 JLg/kg i.v.; the other four were given 7 JLglkg. All subjects received both neostigmine and physostigmine on separate days in randomized order. The third rCBF procedure (run 3) started at the end of the infusion, 25 min after scopolamine injection. Then the BSRT was again administered, and the final rCBF determination was made 75 min from scopol amine injection. The BSRT was repeated at �90 min after scopolamine injection. The main point of interest is run 3, the third rCBF mea surement. Occurring at �25 min from scopolamine admin istration and at the end of the reversal infusion, it should reflect the peak additive effects of scopolamine plus physo stigmine versus scopolamine plus neostigmine, compared with run 2. Figures 1 and 2 give a graphic depiction of the experimental design.
rCBF
Procedures were identical to those described by Honer et al. (1988) . Each cerebral hemisphere was covered by 16 detectors, and pulse rate, blood pressure, and end-tidal Peoz were monitored throughout. The instrument, soft ware, and our quality-control measures have all been de scribed in detail elsewhere (Prohovnik, 1988) . All data analyses presented here pertain to the gray-matter flow (ml lOOg-1 min-I), obtained by the six-unknown model (M2: Prohovnik et aI., 1983) . All flow values were adjusted to an end-tidal Peoz value of 40.6, as suggested by Maximil-ian et al. (1980) to reduce variability, but this operation has no impact on the regional patterns that are of primary interest here.
Data analysis
As in our previous experiments, significant main effects or interactions involving the two hemispheres were not detected, so all regions were bilaterally averaged. The two dependent rCBF variables of central interest for quantitative analysis were the global mean flow and the hyperfrontality (anterior/posterior) ratio. Anterior locations were the regions denoted Fl, F2, F3, F4, and F5 in the standard helmet, located over the frontal lobes, whereas posterior locations included all other 11 regions (from a total of 16 cortical regions). This division was examined because it had emerged as the major effect of scopolamine in the previous experiment, and a topo graphic visualization can be found in the previous report (Honer et aI., 1988) .
Data were analyzed by repeated-measures and multi variate analyses of variance (ANOY A, MANOY A) tech niques (for which the conservative Greenhouse-Geiger corrected p is provided), with the neostigmine dose (high/ low) as a between-subject factor and drug (physostigmine/ neostigmine) and run (1-4) as repeated measures. Re sults are reported with the F ratio, degrees of freedom, and significance level. Specific contrasts are reported as conservative unplanned comparisons, rather than planned post hoc analyses, to further reduce type I error. Analyses were performed with the SuperANOYA package on a Macintosh computer. BSRT scores reflect total immediate recall. Numerical data are provided in the text as the mean ± SD.
RESULTS
Cardiovascular and respiratory changes are pro vided in Table 1 . Systolic blood pressure rose slightly after scopolamine and decreased following cholines terase inhibition, but neither the main time effect nor any interactions approached significance. Diastolic blood pressure showed similar nonsignificant trends.
PCOZ did not show significant effects or interactions, although there was a slight elevation immediately after scopolamine and a decline after both cholines terase inhibitors. The pulse rate showed highly sig nificant changes with time (F3,ZI = 32.23, P < 0.0001); there were slight elevations after scopolamine, marked decreases following the acetylcholinesterase (AChE) inhibitors (from -69 to 55), and partial re covery toward baseline at 75 min. Physostigmine and neostigmine were similar in their effects.
BSRT total recall, the measure of cognitive drug effect, showed a significant time effect (FZ,16 = 20.00, p = 0.0003) and a significant time by drug interaction (F2,16 = 4,06, p < 0.05). To further examine the inter action, a separate analysis was performed on the sec ond BSRT session at 40 min. There was a significant difference between physostigmine and neostigmine (FI,7 = 26.22, p = 0.001), with physostigmine yielding bettcr BSRT performance than neostigmine (127 vs. 116). Of note, there was also a significant interaction with neostigmine dose (F1,7 = 13.27, p < 0.001):
BSRT performance on the high neostigmine dose was almost as good (124) 10.28, p = 0.01). In comparison with the baseline condition as well, flow was higher following physo stigmine and lower following neostigmine, but this comparison was nonsignificant.
The hyperfrontality ratio (Fig. 2) showed a signifi cant change with time (F324 = 11.70, P < 0.001) and a drug by time interaction (F3,24 = 3.59, p < 0.05).
There was an immediate and marked reduction in this ratio following scopolamine. However, there was a short-lived increase of this ratio after physostigmine (from 1.076 to 1.104); neostigmine was associated with a continuous decline at this point (from 1.097 to 1.077). This difference was significant (F1.7 = 7.43, p < 0.03). Specific post hoc contrasts between the drug conditions showed a significant difference only during the third, post-physostigmine run (FJ = 6.21, p < 0.03); the three other conditions were not signifi cantly different. The complete regional change over the cortex from run 2 to run 3 is depicted in Fig. 3 .
DISCUSSION
Replicating our previous reports (Honer et aI., 1988; Gitelman and Prohovnik, 1992) Physotigmine sion by physostigmine adds strong support to this hypothesis. The following discussion will concentrate on the novel observations of neostigmine, limitations of the current study, remaining discrepancies with previous reports, and the mechanism of action of physostigmine.
Neostigmine effects
We were surprised to find the apparent central effects of neostigmine at the higher dose. This medi cation was selected for its poor penetration of the Changes of cortical blood flow (m1/100 g/min) caused by a 10-min infusion of neostigmine or physostigmine, 5 min after injection of scopolamine (7.3 jLg/kg). Data are group means for all subjects and conditions (including both neostigmine doses), depicted as the percentage change of regional flow from before to after AChE inhibitor infusion (100 equals no change). The numbers below depictions denote mean brain changes of flow (+10% for physostigmine, -7% for neostigmine). Note that physostigmine, but not neostigmine, increases hyperfrontality.
compared with physostigmine and showed no effects (Schaffer et aI., 1981 
Limitations of the current study
Although these and previous findings directly im plicate the cholinergic system, and specifically musca rinic pathways, in the global and focal regulation of cortical perfusion, our studies are limited in the separation of metabolic versus vascular effects and cannot exclude an intervening or interacting noncho linergic mechanism. In addition, the current study cannot be generalized to older subjects; as we (Gitcl man and Prohovnik, 1992) and others have noted, aging modifies cholinergic responsivity. Finally, it is not possible to exclude the possibility of very small physostigmine effects in the parietotemporal cortex:
although these effects must be of lesser magnitude and smaller spatial extent, they may be detectable by higher-resolution methods.
The vascular system is densely innervated with cholinergic fibers and receptors, although the specific receptor subtypes are still being debated (Kalaria et aI., 1994 (Sato and Sato, 1992; Fukuyama et aI., 1995) . In contrast, lesions of the NbM are well known to cause reductions of cortical glucose utilization, predominantly in the frontal cortex and in direct cor relation to the reduction of choline acetyltransferase (ChAT) activity (Kiyosawa et aI., 1989 ), suggesting that the physostigmine effects observed here could be metabolically driven.
Other transmitter systems are well known to affect the cerebral cholinergic system and interact with its vasomotor regulation (Sato and Sato, 1992) . Physo stigmine and methylphenidate have been shown to reverse each others ' behavioral effects in psychiatric patients (Janowsky et aI., 1973a) . A scopolamine dose similar to ours has been shown by Dewey et al. (1993) to decrease pI C)raclopride binding in the human stri atum ' consistent with an increase in dopamine re lease. The NbM responds to amphetamine or apo morphine intraperitoneally by increasing cortical acetylcholine (ACh) output (Sato and Sato, 1992) .
Thus, we cannot yet exclude the possibility that some of our observations are due to indirect effects of other neurotransmitter systems, although they are also con-sistent with pure cholinergic mechanisms. In particu lar, as mentioned earlier, there is yet no established anatomical substrate to the apparent frontal predom inance of scopolamine and physostigmine effects; this finding may be due to other interactions (e.g., dopa minergic).
Comparison with previous reports
There is a dearth of literature concerning these effects in humans, and the only previous article that dures, Blin et al. (1994) reported that scopolamine increased glucose metabolism throughout the cortex in elderly healthy subjects, whereas physostigmine administration to AD patients resulted in slight de creases in the posterior cortex and increases in the frontal cortex. Our physostigmine effects are consis tent with these findings in their regional distribution, although the changes observed by Blin et al. (1994) were much weaker and did not reach significance.
This lack of significance might be due to the small sample size (1\= 6), or it might be that physostigmine exerts only weak effects in AD patients whose pre synaptic ACh levels were already depleted. Blood flow may also respond more vigorously than glucose utilization to cholinergic stimulation, as found by Vaucher et al. (1995) . Alternatively, their findings may be due to their long interscan interval (:0;2 weeks). Our study was completed in <2 h on one day for each cholinergic agonist, thus minimizing normal biological variability over time. Another limitation in the FDG-PET procedure may have been the low temporal resolution. The low efficacy of physostig mine in clinical AD trials has been attributed to its very short duration of action (Linville et aI., 1992) .
The current study confirms that physostigmine's effects are rapid and transient. The behavioral pro tective effect was noticeably weaker by 90 min (Fig.   1 ). The effects on mean cortical perfusion and hyper frontality were evident only during run 3 and com pletely dissipated 50 min later (Fig. 2) . Dauphin et al. (1991) reported that cortical perfusion increases In fact, these authors showed that the elimination half-life of physostigmine from most cortical areas (other than occipital and olfactory) ranged from 4 to 10 min. The FDG procedure is usually insensitive to rapid changes, and Blin et al. (1994) were forced to reduce the dose and prolong the scan further to allow for two measurements. Therefore, a transient effect could have been missed. Finally, the doses of physostigmine were dissimilar: whereas we infused 22 jLg/kg over 10 min, Blin et al. infused only 5 jLg/ kg/h. We agree with their caution in using physostig mine in AD patients, since we have run into similar problems (Wirkowski et aI., 1991) . However, it is likely that these methodological problems all limit the power of their very weak physostigmine findings.
Cholinergic muscarinic blockade in general, and scopolamine in particular, are virtually universally stated to reduce cerebral metabolism and blood flow in textbooks (e.g., see references in McCulloch, 1988; Edvinsson et aI., 1993; Kurumaji et aI., 1993 ; but see also exceptions, such as Dauphin et aI., 1991) . It is, therefore, difficult to explain the paradoxical increase of cortical metabolism by scopolamine reported by Blin et al. (1994) . Their dose of 0.25 mg/m 2 of body surface area would result in about 0.43 mg in a stan dard adult, �20% lower than our dose of 7.2 jLg/kg; furthermore, they administered it by slow infusion, whereas ours was a bolus injection. In our original experiment (Honer et aI., 1988) , we showed that the dose/response curve was rather steep at these ranges, and, at least in young subjects, this difference could be consequential. Ray et al. (1991) documented an equally strong difference between the P100 visual evoked potential effects of 4 and 7 jLg/kg doses in young and middle-aged (but not elderly) subjects.
The delay of FDG injection until an hour after sco polamine administration, and the low temporal reso lution discussed earlier, would further reduce the effect. Blin et al. (1994) acknowledge that their results are inconsistent with rCBF findings in humans and FDG findings in rodents and suggest, among other possibilities, that scopolamine decouples perfusion from glucose metabolism in humans. Such decoupling is also indicated by the recent report of Ogawa et al. (1994) , who measured both CBF and CMR g lc in cats with PET during somatosensory stimulation. Al though they do not provide the actual data, these authors stated that the contralateral rCBF activa tion was abolished by scopolamine (350 jLg/kg i.v.), whereas the metabolic response was preserved. How ever, Ogawa et al. (1994) argue only that scopolamine changes the activation response coupling, not the 1. PROHOVNIK ET AL.
baseline tone: according to their results, scopolamine does reduce resting metabolism and blood flow. In humans, however, Molchan et ai. (1994) also failed to find substantial reductions of glucose metabolism (by FDG-PET) after 0.5 mg of scopolamine (i.v.).
That group did report weak reductions in prefrontal cortex, consistent with the location of our findings.
Thus, although there are similarities in FDG-PET findings for both physostigmine and scopolamine, they are weaker and require further clarification.
Mechanisms of action
This is the third observation, and second indepen dent replication, in the frontal locus of scopolamine induced perfusion deficits in healthy humans. We have previously shown that this effect is dose-depen dent (Honer et ai., 1988) and can be seen in both young and elderly subjects (Gitelman and Prohovnik, 1992 (Dauphin et ai., 1991; Vaucher et ai., 1994) . In conscious rats, SI lesions reduce ChAT activity mostly in the frontal cortex but do not reduce the flow to the same extent or in exactly the same regions (Peruzzi et ai., 1993) . Physostigmine, in the same experiment, caused widespread cortical vasodi latation independent of SI lesions. The authors con cluded that physostigmine does not act through the SI system but, instead, directly on cortical interneurons.
Alternatively, it was recently reported that the den sity of nitric oxide synthase-positive neurons in the frontal cortex of the rat is significantly higher than in other cortical regions; these neurons bear muscarinic receptors and may mediate the vascular effects pro jecting from the basal forebrain (Moro et ai., 1995) .
Physostigmine distribution in the rodent brain has been studied (Scremin et ai., 1990), and the flow elevations do not correspond to areas of high initial concentration, that is, they are not a function of acces sibility and availability. The current findings of rever sal of scopolamine-induced hypofrontality with phy sostigmine, but not neostigmine, offer strong support for the centrality of the frontal cortex in the responses of the human brain to cholinergic manipUlations.
Our study also sheds new light on the cerebral action of physostigmine. Because this drug shows a therapeutic benefit in AD, authors previously at tempted to find that it also ameliorated the parieto temporal perfusion deficit characteristic of that dis- Our study is the first to quantify a frontal cortex effect in tight association with a memory test effect.
There is other preliminary evidence, though far from definitive, that the frontal cortex is a major target for cholinergic manipulations involving AChE inhibi tion. Ebmeier et ai. (1992) reported a relative in crease of perfusion (uptake with single photon emis sion computed tomography) in the superior frontal cortex and a decrease in the left parietotemporal cortex, in response to a dose of velnacrine, another AChE inhibitor, that slightly improved word recogni tion memory. We have shown such effects with ta crine, the only medication currently approved for treatment of AD. In a preliminary study (Prohovnik et ai., 1994) , we measured rCBF in three patients who received 80 mg tacrine orally for 8 weeks. Mean cortical perfusion rose by � 10%. Preliminary FDG PET data are consistent with this finding (Nordberg, 1993) . The greatest and most consistent changes were seen in frontal cortex areas. Finally, there is increas ing clinical and neuropsychological evidence that such drugs, and especially tacrine, exert their maxi mal effect on attentional mechanisms, rather than the core amnestic syndrome of AD (Sahakian et ai., 1993) ; this finding would suggest a frontal cortex locus of action.
In conclusion, this experiment fully replicates the scopolamine-induced frontal deficit first reported by Honer et ai. (1988) . Moreover, this experiment con firms that both the perfusion hypofrontality and the memory deficit induced by scopolamine in young healthy subjects are reversible by physostigmine, but not neostigmine. Therefore, both depend on centrally mediated cholinergic effects, rather than peripheral side effects, and seem to be primarily related to the frontal cortex. We do not yet have an explanation for the frontal site of action, and it remains to be established whether these findings support or refute the "scopolamine model" of AD. However, to the extent that the scopolamine hypocholinergic state is a valid simulation, our findings suggest that the bene ficial effects of physostigmine and, by extension, other AChE inhibitors depend on frontal lobe mech anisms and may specifically improve those higher cognitive functions, such as attentional mechanisms, that indirectly affect memory performance. In this area, our findings support recent observations on the therapeutic actions of tacrine in AD.
